PR1A3
Alternative Names: Anti-mCEA monoclonal antibody PR1A3; Monoclonal antibody PR1A3Latest Information Update: 27 Jun 2005
Price :
$50 *
At a glance
- Originator Cancer Research UK
- Developer Antisoma; Cancer Research UK
- Class Monoclonal antibodies; Monoclonal antibody diagnostics; Radiopharmaceutical diagnostics
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Colorectal cancer
Most Recent Events
- 27 Jun 2005 Discontinued - Preclinical for Cancer in United Kingdom (unspecified route)
- 22 Dec 1998 Preclinical development for Cancer in United Kingdom (unspecified route)